GPX4 and cancer: Since then, research has been conducted using various ferroptosis inducers, including erastin as an SLC7A inhibitor and RSL3 as a GPX4 inhibitor, to explore the anticancer effects of these compounds regardless of RAS mutation and to overcome therapy resistance in various cancer cells11–20.